Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer

Detalles Bibliográficos
Autores principales: Urbanska, Edyta M., Sørensen, Jens B., Melchior, Linea C., Costa, Junia C., Santoni-Rugiu, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489192/
https://www.ncbi.nlm.nih.gov/pubmed/35797511
http://dx.doi.org/10.1200/PO.22.00040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489192/
https://www.ncbi.nlm.nih.gov/pubmed/35797511
http://dx.doi.org/10.1200/PO.22.00040

Ejemplares similares